Compare CZFS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | SLGL |
|---|---|---|
| Founded | 1984 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 247.1M |
| IPO Year | 1995 | 2016 |
| Metric | CZFS | SLGL |
|---|---|---|
| Price | $63.11 | $70.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 3.2K | ★ 14.0K |
| Earning Date | 04-29-2026 | 05-22-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 30.26 | N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $9,881,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.64 | $223.84 |
| P/E Ratio | $29.22 | ★ N/A |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $49.99 | $6.80 |
| 52 Week High | $69.58 | $97.97 |
| Indicator | CZFS | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 48.36 |
| Support Level | $57.20 | $67.47 |
| Resistance Level | $69.05 | $81.66 |
| Average True Range (ATR) | 1.78 | 5.47 |
| MACD | -0.22 | -0.11 |
| Stochastic Oscillator | 51.71 | 37.98 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.